2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Edwards Lifesciences company profile · structural heart & critical care medical devices · history · financial snapshot · S&P 500 rank #222 · 愛德華生命科學公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | EW (NYSE) |
| Company | Edwards Lifesciences Corporation |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment & Supplies |
| S&P 500 rank (by weight) | #222 · 0.08% (Oct 30, 2026) |
| Sector rank (by market cap) | #28 in Health Care (Oct 30, 2026) |
| Share price (frozen benchmark) | $92.01 (Oct 30, 2026) |
| Headquarters | Irvine, California |
| Founded | 1958 (by Miles Lowell Edwards) |
| CEO | Bernard J. Zovighian (CEO) |
| Employees | about 16,000 (2025) |
| Market cap | $53.03B (Oct 30, 2026) |
WHAT IT DOES
Edwards Lifesciences is a medical technology company focused on structural heart disease and critical care monitoring. Its flagship products are transcatheter heart valves — principally the SAPIEN platform — plus surgical heart valves, transcatheter mitral and tricuspid therapies, and monitoring systems used in operating rooms and intensive care units.
The model is procedure-driven: each valve implant generates device revenue, and growth follows procedure volumes, new indications and geographic expansion. FY2025 net sales were $6,068M, up 11.5% from $5,440M, gross profit was $4,733M, operating income was $1,636M and net income was $1,074M.
FY2024 net income of $4,175M was inflated by a large one-time gain, so the FY2025 decline in net income is not a business decline — it is the absence of that gain. Year-over-year net income comparisons must carry that context.
BUSINESS SEGMENTS — FY2025 NET SALES
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Transcatheter Heart Valve Therapy | — | — | — |
| Surgical Structural Heart | — | — | — |
| Transcatheter Mitral and Tricuspid Therapies | — | — | — |
HISTORY
| Year | Milestone |
|---|---|
| 1958 | Founded by Miles Lowell Edwards, inventor of the first medically proven artificial heart valve |
| 1960 | The first Starr-Edwards mitral valve is successfully placed in a patient |
| 1985 | Acquired by Baxter International |
| 2000 | Spins off from Baxter and lists on the New York Stock Exchange |
| 2023 | Bernard J. Zovighian becomes CEO |
| 2025 | FY2025 net sales reach $6,068M, up 11.5% |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Net sales | $6,068M (+11.5% YoY) |
| Gross profit | $4,733M |
| Operating income | $1,636M |
| Net income | $1,074M |
| Prior-year net income (FY2024) | $4,175M (includes a large one-time gain) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Edwards is the S&P 500's structural-heart name: at a 0.08% index weight and #28 in Health Care by market cap, it is the index's main exposure to transcatheter heart valves.
Its procedure growth is a standing read on cardiovascular intervention demand — valve volumes move with aging and diagnosis before they show up in hospital procedure revenue.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close) |
| Financials | Edwards Lifesciences FY2025 results (fiscal year ended Dec 31, 2025), company profile sources |
| Sector classification | GICS (Health Care Equipment & Supplies) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | EW(NYSE) |
| 公司 | Edwards Lifesciences Corporation |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備與用品 |
| 標普500排名(按權重) | #222 · 0.08%(2026 年 10 月 30 日) |
| 板塊內排名(按市值) | 醫療保健第 #28(2026 年 10 月 30 日) |
| 股價(凍結基準) | $92.01(2026 年 10 月 30 日) |
| 總部 | 美國加州爾灣 |
| 成立 | 1958 年(Miles Lowell Edwards 創辦) |
| 行政總裁 | Bernard J. Zovighian(行政總裁) |
| 員工 | 約 16,000(2025 年) |
| 市值 | $53.03B(2026 年 10 月 30 日) |
業務概覽
愛德華生命科學是一家醫療科技公司,專注於結構性心臟病與重症監護監測。旗艦產品為經導管心臟瓣膜——主要為 SAPIEN 平台——以及外科心臟瓣膜、經導管二尖瓣與三尖瓣療法,及手術室與深切治療部使用的監測系統。
其模式以手術量驅動:每次瓣膜植入帶來裝置收入,增長跟隨手術量、新適應症與地區擴張。FY2025 淨銷售額為 $6,068M,同比增長 11.5%(FY2024 為 $5,440M),毛利為 $4,733M,營業利潤為 $1,636M,淨利潤為 $1,074M。
FY2024 淨利潤 $4,175M 因一項大額一次性收益而膨脹,故 FY2025 淨利潤下跌並非業務下滑——而是該收益不再出現。同比淨利潤比較須附此背景。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 經導管心臟瓣膜療法 | — | — | — |
| 外科結構性心臟 | — | — | — |
| 經導管二尖瓣與三尖瓣療法 | — | — | — |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1958 | 由首個人工心臟瓣膜醫學驗證發明者 Miles Lowell Edwards 創辦 |
| 1960 | 首個 Starr-Edwards 二尖瓣成功植入患者體內 |
| 1985 | 被 Baxter International 收購 |
| 2000 | 由 Baxter 分拆並在紐約證券交易所上市 |
| 2023 | Bernard J. Zovighian 出任行政總裁 |
| 2025 | FY2025 淨銷售額達 $6,068M,同比增長 11.5% |
競爭地位
財務快照 — FY2025
| 淨銷售額 | $6,068M(同比 +11.5%) |
| 毛利 | $4,733M |
| 營業利潤 | $1,636M |
| 淨利潤 | $1,074M |
| 上年度淨利潤(FY2024) | $4,175M(含大額一次性收益) |
主要風險
對標普500的重要性
愛德華是標普500的結構性心臟標的:指數權重 0.08%、醫療保健板塊市值第 #28,是指數對經導管心臟瓣膜的主要敞口。
其手術增長,是心血管介入需求的常設讀數——瓣膜量隨老齡化與診斷變動,往往先於醫院手術收入反映。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤) |
| 財務 | 愛德華生命科學 FY2025 業績(財政年度截至 2025 年 12 月 31 日)、公司簡介來源 |
| 板塊分類 | GICS(醫療保健設備與用品),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-31 11:45 · updated 2026-11-14 23:24 · rev 7